UPDATE 1-Cerevel Therapeutics' Parkinson's disease drug meets main goal in late-stage study

Reuters04-18

(Adds details throughout)

April 18 (Reuters) - Cerevel Therapeutics said on Thursday its Parkinson's disease drug met the main goal of a late-stage trial.

The trial was testing the drug tavapadon as an add-on therapy to levadopa, the standard of care for Parkinson's disease.

The results showed that patients using these two drugs had a statistically significant increase in the time in which they had good control over symptoms -- such as uncontrolled, involuntary muscle movement -- than patients given levadopa and a placebo.

(Reporting by Sriparna Roy and Puyaan Singh in Bengaluru; Editing by Savio D'Souza)

((Sriparna.Roy@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2428690505?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-18 18:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2428690505","market":"us","top_or_hot":-1,"title":"UPDATE 1-Cerevel Therapeutics' Parkinson's disease drug meets main goal in late-stage study","media":"Reuters","content":"<html><body><p>(Adds details throughout)</p><p>      April 18 (Reuters) - Cerevel <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>    said on Thursday its Parkinson's disease drug met the main goal of a late-stage trial.</p><p>   The trial was testing the drug tavapadon as an add-on therapy to levadopa, the standard of care for Parkinson's disease.</p><p>   The results showed that patients using these two drugs had a statistically significant increase in the time in which they had good control over symptoms -- such as uncontrolled, involuntary muscle movement -- than patients given levadopa and a placebo.</p><p> (Reporting by Sriparna Roy and Puyaan Singh in Bengaluru; Editing by Savio D'Souza)</p><p>((Sriparna.Roy@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UPDATE 1-Cerevel Therapeutics' Parkinson's disease drug meets main goal in late-stage study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUPDATE 1-Cerevel Therapeutics' Parkinson's disease drug meets main goal in late-stage study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-18 18:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Adds details throughout)      April 18 (Reuters) - Cerevel Therapeutics    said on Thursday its Parkinson's disease drug met the main goal of a late-stage trial.   The trial was testing the drug ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CERE","symbol_name":"Cerevel Therapeutics Holdings, Inc.","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2428690505","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2428690505","pubTimestamp":1713437502,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"(Adds details throughout)      April 18 (Reuters) - Cerevel Therapeutics    said on Thursday its Parkinson's disease drug met the main goal of a late-stage trial.   The trial was testing the drug tava","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CERE":"Cerevel Therapeutics Holdings, Inc.","BK4139":"生物科技","LENZ":"Therapeutics"},"translate_title":"更新1-Cerevel Therapeutics的帕金森病药物在后期研究中达到主要目标","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"CERE":0.9},"content_text":"(Adds details throughout)      April 18 (Reuters) - Cerevel Therapeutics    said on Thursday its Parkinson's disease drug met the main goal of a late-stage trial.   The trial was testing the drug tavapadon as an add-on therapy to levadopa, the standard of care for Parkinson's disease.   The results showed that patients using these two drugs had a statistically significant increase in the time in which they had good control over symptoms -- such as uncontrolled, involuntary muscle movement -- than patients given levadopa and a placebo. (Reporting by Sriparna Roy and Puyaan Singh in Bengaluru; Editing by Savio D'Souza)((Sriparna.Roy@thomsonreuters.com;))","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2428690505"}